Philip Robson Therapeutic aspects of cannabis and cannabinoids 2001
Summary:

“Cannabis and some cannabinoids are effective antiemetic’s and
analgesics and reduce intraocular pressure. There is evidence of symptom relief and
improved well-being in selected neurological conditions, AIDS and certain cancers.
Cannabinoids may reduce anxiety and improve sleep. Anticonvulsant activity
requires clarification. Other properties identified by basic research await evaluation.
Standard treatments for many relevant disorders are unsatisfactory. Cannabis is safe
in overdose but often produces unwanted effects, typically sedation, intoxication,
clumsiness, dizziness, dry mouth, lowered blood pressure or increased heart rate.
The discovery of specific receptors and natural ligands may lead to drug
developments. Research is needed to optimise dose and route of administration,
quantify therapeutic and adverse effects, and examine interactions.”

Their conclusion (House of Lords, 1998) published in November 1998, was that,
although cannabis should remain a controlled drug, the law should be changed to
allow doctors to prescribe “an appropriate preparation of cannabis if they saw fit”, and “search for a way to avoid criminalising those who seek only to assuage their own
suffering”. The government rejected this recommendation on the day of publication.

Therapeutic aspects of cannabis and cannabinoids

Mike Barnes Report on Cannabis:

The Evidence for Medical Use 2016.  A comprehensive review of the literature about cannabis for therapeutic purposes.

Cannabis – The Evidence for Medical Use –  Professor Michael P Barnes MD FRCP

The Wootton Report 1969:

The Wootton Report 1969

Cannabinoids: A new hope for breast cancer therapy?

This review summarizes our current knowledge on the anti-tumour potential of
cannabinoids in breast cancer, which suggests that cannabinoid-based medicines
may be useful for the treatment of most breast tumour subtypes.

Cannabinoids:  A new hope for breast cancer therapy?

Medical cannabis and mental health: A guided systematic review

Mental health conditions are prominent among the reasons for medical cannabis use.

Cannabis has potential for the treatment of PTSD and substance use disorders.
Cannabis use may influence cognitive assessment, particularly with regard to
memory.

Cannabis use does not appear to increase risk of harm to self or others.
More research is needed to characterize the mental health impact of medical cannabis.

Clinical Psychology Review – Medical cannabis and mental health: A guided systematic review

Cannabinoids and Alzheimers

“Cannabinoids remove plaque-forming Alzheimer’s proteins from brain cells
Scientists have found preliminary evidence that tetrahydrocannabinol (THC) and other
compounds found in marijuana can promote the cellular removal of amyloid beta, a toxic
protein associated with Alzheimer’s disease.”

“Although other studies have offered evidence that cannabinoids might be
neuroprotective against the symptoms of Alzheimer’s, we believe our study is the first to demonstrate that cannabinoids affect both inflammation and amyloid beta accumulation
in nerve cells” says Salk Institute Professor David Schubert, the senior author of the paper.

Cannabinoids remove plaque-forming Alzheimer’s proteins from brain cells

Harvard: Marijuana Doesn’t Cause Schizophrenia:

The researchers concluded that the results of the current study, “both when analysed
using morbid risk and family frequency calculations, suggest that having an
increased familial risk for schizophrenia is the underlying basis for schizophrenia in
these samples – not the cannabis use.

“While cannabis may have an effect on the age of onset of schizophrenia it is unlikely
to be the cause of illness,” said the researchers, who were led by Ashley C. Proal
from Harvard Medical School.

Harvard: Marijuana Doesn’t Cause Schizophrenia